Cardiff Oncology (CRDF) Financials: History & Chart

Cardiff Oncology, Inc.(CRDF)

Biotechnology · San Diego, CA

$1.08-0.06 (-5.26%)

Delayed quote: Oct 6, 2026, 2:52 PM EDT

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

San Diego, CA

31 employees

www.cardiffoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mani Mohindru

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	508K	104K	41K	243K	120K	121K	109K	151K	165K
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	11.58M	0.00	0.00	9.64M
Gross Profit	508K	104K	41K	243K	120K	-11.46M	109K	151K	-9.47M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	-9470.2%	100.0%	100.0%	-5742.4%
Total Operating Expenses	42.77M	9.72M	12.89M	8.07M	12.09M	3.32M	14.49M	12.72M	3.13M
Research & Development	25.95M	5.92M	6.76M	5.08M	8.20M	11.58M	10.48M	9.71M	9.64M
Selling, General & Administrative	16.82M	3.80M	6.13M	3.00M	3.90M	0.00	4.01M	3.01M	0.00
Operating Income (EBIT)	-42.27M	-9.62M	-12.85M	-7.83M	-11.97M	-14.78M	-14.38M	-12.57M	-12.60M
Operating Margin	-8320.1%	-9245.2%	-31341.5%	-3221.0%	-9978.3%	-12212.4%	-13194.5%	-8325.8%	-7637.0%
Income Before Tax (EBT)	-40.05M	-9.23M	-12.35M	-7.22M	-11.26M	-13.94M	-13.43M	-11.79M	-11.86M
Interest Income	2.22M	382K	506K	612K	716K	835K	941K	787K	741K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	2.21M	383K	505K	611K	716K	834K	948K	785K	746K
Net Income	-40.05M	-9.23M	-12.35M	-7.22M	-11.26M	-13.94M	-13.43M	-11.79M	-11.86M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-7884.1%	-8876.9%	-30109.8%	-2969.5%	-9381.7%	-11523.1%	-12324.8%	-7806.0%	-7184.8%
EBITDA	-41.15M	-9.44M	-12.63M	-7.60M	-11.48M	-14.68M	-14.15M	-12.48M	-12.50M
EBITDA Margin	-8101.2%	-9077.9%	-30802.4%	-3129.2%	-9566.7%	-12134.7%	-12985.3%	-8262.3%	-7575.8%
Depreciation & Amortization	1.11M	174K	221K	223K	494K	94K	228K	96K	101K
EPS Basic	-0.60	-0.14	-0.18	-0.11	-0.17	-0.21	-0.28	-0.25	-0.25
EPS Diluted	-0.60	-0.14	-0.18	-0.11	-0.17	-0.21	-0.28	-0.25	-0.25
Weighted Average Basic Shares	68.40M	68.40M	68.35M	66.84M	66.88M	66.53M	47.65M	47.65M	46.87M
Weighted Average Diluted Shares	68.40M	68.40M	68.35M	66.84M	66.88M	66.53M	47.65M	47.65M	46.87M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	593K	683K	488K	386K	359K	366K	245K	378K
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	0.00	0.00	597K
Gross Profit	593K	683K	488K	386K	359K	366K	245K	-219K
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	-57.9%
Total Operating Expenses	49.55M	49.33M	45.90M	40.29M	29.21M	19.45M	16.92M	16.17M
Research & Development	35.33M	36.85M	32.86M	27.11M	17.38M	11.23M	11.16M	8.16M
Selling, General & Administrative	14.22M	12.48M	13.04M	13.18M	11.84M	8.22M	5.76M	8.01M
Operating Income (EBIT)	-48.96M	-48.65M	-45.41M	-39.90M	-28.86M	-19.09M	-16.68M	-17.05M
Operating Margin	-8256.3%	-7123.1%	-9305.7%	-10337.3%	-8037.6%	-5214.8%	-6817.8%	-4511.4%
Income Before Tax (EBT)	-45.85M	-45.43M	-41.44M	-38.70M	-28.29M	-19.31M	-16.41M	-16.46M
Interest Income	3.10M	3.26M	4.07M	1.58M	264K	90K	234K	219K
Interest Expense	N/A	N/A	N/A	N/A	N/A	2K	N/A	25K
Other Income/Expense	3.11M	3.22M	3.97M	1.20M	564K	-221K	264K	-72K
Net Income	-45.85M	-45.43M	-41.44M	-38.70M	-28.29M	-19.31M	-16.41M	-16.46M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	618K
Net Profit Margin	-7732.0%	-6651.7%	-8492.0%	-10026.9%	-7880.5%	-5275.1%	-6709.7%	-4354.8%
EBITDA	-48.06M	-48.25M	-45.01M	-39.67M	-28.40M	-18.62M	-16.18M	-16.32M
EBITDA Margin	-8103.9%	-7064.0%	-9224.2%	-10276.2%	-7912.0%	-5087.4%	-6615.8%	-4316.6%
Depreciation & Amortization	904K	404K	398K	236K	451K	466K	494K	736K
EPS Basic	-0.69	-0.95	-0.93	-0.89	-0.73	-1.08	-2.70	-7.06
EPS Diluted	-0.69	-0.95	-0.93	-0.89	-0.73	-1.08	-2.70	-7.06
Weighted Average Basic Shares	66.84M	47.65M	44.68M	43.60M	39.03M	20.88M	5.97M	2.33M
Weighted Average Diluted Shares	66.84M	47.65M	44.68M	43.60M	39.03M	20.88M	5.97M	2.33M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.